PT  - JOURNAL ARTICLE
AU  - CHAMBERLAIN, FLORENCE
AU  - ENGELMANN, BODIL
AU  - AL-MUDERIS, OMAR
AU  - MESSIOU, CHRISTINA
AU  - THWAY, KHIN
AU  - MIAH, AISHA
AU  - ZAIDI, SHANE
AU  - CONSTANTINIDOU, ANASTASIA
AU  - BENSON, CHARLOTTE
AU  - GENNATAS, SPYRIDON
AU  - JONES, ROBIN L.
TI  - Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
AID  - 10.21873/invivo.11766
DP  - 2020 Jan 01
TA  - In Vivo
PG  - 239--245
VI  - 34
IP  - 1
4099  - http://iv.iiarjournals.org/content/34/1/239.short
4100  - http://iv.iiarjournals.org/content/34/1/239.full
SO  - In Vivo2020 Jan 01; 34
AB  - Background: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. Patients and Methods: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. Results: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). Conclusion: Conventional systemic therapy has limited efficacy in advanced LGFMS.